July 25, 2015 / 10:29 PM / 3 years ago

Teva in talks to buy Allergan big generic-drug unit: WSJ

Teva Pharmaceutical Industries' Jerusalem oral solid dosage plant (OSD) is seen December 21, 2011. REUTERS/Ronen Zvulun

(Reuters) - Israeli drug maker Teva Pharmaceutical Industries Ltd (TEVA.TA) is in talks to combine with Allergan Plc’s (AGN.N) big generic-drug business, the Wall Street Journal reported on Saturday, citing people familiar with the matter.

A deal for the Allergan business, valued at about $45 billion, could be announced as early as Monday, one of the people said, according to the Journal. The Allergan unit would be spun off and combined with Teva, which has a market value of $60 billion, this person told the newspaper.

Reporting by Eric Beech in Washington; Editing by Bernard Or

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below